Bruker Daltonics and Leiden University Medical Center Announce Biomarker Discovery and Clinical Proteomics Collaboration
BILLERICA, Mass. & LEIDEN, The Netherlands--(BUSINESS WIRE)--Dec.
4, 2003--Bruker Daltonics Inc., an operating company of Bruker
BioSciences Corp. (NASDAQ: BRKR) and the Leiden University Medical
Center (LUMC) today announced an advanced research collaboration on
biomarker discovery and clinical proteomics. Building on the success
of an earlier collaboration, the LUMC has acquired four new mass
spectrometry systems, as well as clinical proteomics sample
preparation and bioinformatics solutions, from Bruker Daltonics. The
LUMC will provide feedback on instrumentation, methods and software
development for clinical research to Bruker Daltonics.
Professor Dr. Andre M. Deelder, Program Leader in the LUMC
Department of Parasitology, explained: "As an extension of our already
on-going collaboration with Bruker Daltonics, our (glyco-) proteomics
group will be using a new esquire HCT high capacity ion trap mass
spectrometer for glycan analysis. Another HCT ion trap will be used
for proteomics work in general. We have had a high degree of success
with our Ultraflex TOF/TOF mass spectrometer, and are now adding a
second one. In addition, we will be installing an Apex-Q 9.4 Tesla
hybrid Q-q-FTMS system incorporating the practical ESI/MALDI
Combisource, and a ECD/IRMPD accessory for post-translational
modification studies. The APEX-Q and the second Ultraflex TOF/TOF will
be used for clinical proteomics and glycoprotein research. Our group
really values the high quality support and service we have received
from Bruker Daltonics' applications laboratories in Europe."
Dr. Rob Tollenaar, Principal Investigator in the Department of
Surgery's translational research project, added: "We will use this
highly advanced mass spectrometry platform within the framework of our
comprehensive diagnostic and prognostic biomarker research program for
the analysis of serum and tissue samples. Our research is focused on
the improvement of surgical cancer treatment, especially for
colorectal, breast and gastric cancer, as well as cancer diagnosis.
The department performs clinical research in phase I, II, and III
studies, and laboratory research, including research in animal models.
This novel mass spectrometry instrumentation will play an important
role in clinical research here at LUMC."
Frank Laukien, Ph.D., President and CEO of Bruker Daltonics
stated: "Research scientists and clinicians see our ClinProt(TM)
clinical proteomics system as a very powerful tool for biomarker
discovery and the development of clinical proteomics assays. Our
MALDI-TOF and TOF/TOF systems already have become an important
molecular diagnostics research platform for peptide and protein
biomarker panels that need the multi-channel measurement advantage of
mass spectrometry. Now, our ClinProt automation and bioinformatics
solution can also integrate ultra-high resolution LC/FTMS."
He continued: "We are very pleased to be working with leading
proteomics scientists and clinicians like Professor Deelder and Dr.
Tollenaar in this rapidly developing field of clinical proteomics. It
is our privilege to have excellent relations with the Dutch scientific
and clinical research community. Earlier, our first APEX-Q in Europe
was acquired by the University of Amsterdam in a proteomics research
collaboration, and now LUMC has placed the largest mass spectrometry
order which we have ever received in The Netherlands for utilizing
high-field hybrid FTMS, TOF/TOF and ion traps for clinical proteomics
ABOUT THE LEIDEN UNIVERSITY MEDICAL CENTER
The Leiden University Medical Center is one of several academic
medical centers in the Netherlands. The core tasks of the LUMC are
patient care (routine care, high-level clinical care, and in
particular, high-level reference care); research (both fundamental and
bedside, healthcare-oriented research); education in medicine and
biomedical sciences; specialist medical training; and additional
training, both post-doctoral and post-vocational. The LUMC comprises
the Leiden University Hospital and the Faculty of Medicine of Leiden
University. The LUMC employs approximately 7000 people. For further
information, please visit
ABOUT BRUKER BIOSCIENCES
Bruker BioSciences, headquartered in Billerica, Massachusetts, is
the publicly traded parent company of Bruker Daltonics Inc. and Bruker
AXS Inc. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. Bruker AXS
is a leading developer and provider of life science and advanced
materials research tools based on X-ray technology. For more
information about Bruker BioSciences Corporation, please visit
CAUTIONARY STATEMENT OF BRUKER BIOSCIENCES
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the companies'
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the companies' products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-K for the year ended December 31,
2002, our most recent quarterly reports on Form 10-Q, our current
reports on Form 8-K and the joint proxy statement/prospectus filed in
connection with the merger. We disclaim any intent or obligation to
update these forward-looking statements.
CONTACT: Bruker BioSciences Corporation
Michael Willett, 978-663-3660, ext. 1411
SOURCE: Bruker Daltonics Inc.